甘酸A通过通过微生物三甲代谢调节AhR活动来缓解炎症性肠病
Rong-Wei Kou1, Zhi-Qing Li2, Jia-Lin Wang2
1School of Science, Xi'an University of Technology, Xi'an 710048, Shaanxi, People's Republic of China.
Journal of agricultural and food chemistry
|July 30, 2024
概括
来自Ganoderma lucidum的甘酸A (GAA) 通过调节肠道微生物群和酸盐代谢来预防小鼠的结肠炎. 这种营养干预措施对治疗炎症性肠病 (IBD) 有希望.
科学领域:
- 胃肠病学 胃肠病学
- 微生物学 微生物学
- 免疫学 免疫学 免疫学
背景情况:
- 炎症性肠病 (IBD) 涉及复杂的遗传,微生物和环境因素.
- 肠道微生物群失调是IBD的一个关键因素和潜在的治疗点.
- 甘酸A (GAA) 是一种来自Ganoderma lucidum的化合物,可以调节肠道失调.
研究的目的:
- 研究甘酸A (GAA) 在炎症性肠病 (IBD) 中的治疗潜力.
- 阐明GAA改善IBD症状和改善肠道屏障功能的机制.
主要方法:
- 使用德克斯硫酸 (DSS) 诱导的大肠炎小鼠模型来模拟IBD.
- 管理GAA并评估其对大肠炎,上皮质完整性和肠道微生物群组成的影响.
- 研究了酸代谢,酸受体 (AhR) 激活和IL-22的产生.
- 进行了便微生物群移植,以确认肠道微生物群的作用.
主要成果:
- GAA有效地预防了结肠炎的发展,并保持了上皮质和粘液层的完整性.
- GAA调节了肠道微生物群的组成,促进了氨酸代谢,增加了3岁的代谢.
- GAA激活了基碳化合物受体 (AhR) 并诱导IL-22的产生,这对肠道健康至关重要.
- 便微生物群移植证实,肠道微生物群调解GAA的保护作用.
结论:
- 甘酸A (GAA) 显示出作为改善IBD的营养干预措施的巨大潜力.
- GAA通过影响肠道微生物群,调节酸盐代谢,增强AhR介导的免疫反应来发挥其治疗作用.
- GAA改善了肠道屏障功能,为IBD管理提供了一个有前途的途径.
相关概念视频
Inflammatory Bowel Disease IV: Pharmacological Management
124
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
124
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
149
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
149
Drugs for Treatment of Ulcerative Colitis in IBD
133
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
133
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
124
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
124
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
110
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
110
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
331
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
331


